High Frequency Deep Sclerotomy (HFDS) ab Interno a Combination Surgical Intervention Using Cataract Surgery to Lower IOP

NCT ID: NCT02312362

Last Updated: 2014-12-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

108 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-11-30

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Objective:

To compare intraocular pressure lowering effect of combined sclerotomy ab interno with phacoemulsification and phacoemulsification alone, in primary or secondary open angle glaucoma patients.

Study design:

Prospective, randomized, case- control interventional surgical trial

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cataract Glaucoma POAG

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

HFDS ab interno MIGS surgery

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Combined sclerotomy ab interno and phaco

Combined sclerotomy ab interno and phacoemulsification with IOL implantation

Group Type EXPERIMENTAL

Combined sclerotomy ab interno and phaco

Intervention Type PROCEDURE

Phacoemulsification with IOL implantation

Phacoemulsification with IOL implantation

Group Type ACTIVE_COMPARATOR

Phacoemulsification with IOL implantation

Intervention Type PROCEDURE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Combined sclerotomy ab interno and phaco

Intervention Type PROCEDURE

Phacoemulsification with IOL implantation

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

High Frequency Deep Sclerotomy (=HFDS) HFDS STT (formerly) abee tip Cataract surgery combined with HFDS Phacoemulsification Phaco Cataract Surgery

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients suffering from primary open-angle glaucoma (POAG) inadequately controlled with maximum tolerated medical therapy and who will be treated with cataract surgery.

Exclusion Criteria

* One eyed patients
* Unwilling or unable to give consent, unwilling to accept randomization, or unable to return for scheduled protocol visits
* The presence of extreme narrow angle with complete or partial closure in either eye, except for occludable angles treated with a patent iridectomy
* Any abnormality preventing reliable applanation tonometry, any opacity or patient uncooperativeness that would restrict adequate examination of the ocular fundus or anterior chamber of either eye
* The risk of visual field or visual acuity worsening as a consequence of participation in the trial, in the investigator's opinion
* Any clinically significant, serious, or severe medical or psychiatric condition; any condition that, in the investigator's opinion, would interfere with optimal participation in the study or present a special risk to the patient
* Participation in any other investigational study within 30 days prior to baseline visit
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Geneva, Switzerland

OTHER

Sponsor Role collaborator

Oertli Instrumente AG

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Farhad Hafezi, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Geneva, Switzerland

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Aswān, , Egypt

Site Status COMPLETED

Kiel, , Germany

Site Status RECRUITING

Mumbai, , India

Site Status RECRUITING

Geneva, , Switzerland

Site Status RECRUITING

Reinach, , Switzerland

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt Germany India Switzerland

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Lothar Knuenz

Role: CONTACT

Email: [email protected]

References

Explore related publications, articles, or registry entries linked to this study.

Pajic B, Pajic-Eggspuehler B, Haefliger I. New minimally invasive, deep sclerotomy ab interno surgical procedure for glaucoma, six years of follow-up. J Glaucoma. 2011 Feb;20(2):109-14. doi: 10.1097/IJG.0b013e3181dddf31.

Reference Type BACKGROUND
PMID: 20520572 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HFDS_PS_v9

Identifier Type: -

Identifier Source: org_study_id